Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03400150 Recruiting - Prostate Cancer Clinical Trials

ProSpaceā„¢ Balloon System Pivotal Study BP-007

Start date: January 3, 2018
Phase: N/A
Study type: Interventional

The ProSpaceā„¢ System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the ProSpace System to reduce the radiation dose delivered to the anterior rectum. ProSpace is a balloon composed of a biodegradable material that maintains that space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.

NCT ID: NCT03397160 Recruiting - Prostate Cancer Clinical Trials

Pioneering Advances in Care and Education (PACE)

PACE
Start date: October 10, 2017
Phase: N/A
Study type: Interventional

This clinical trial evaluates the use of novel decision support educational materials and services using health coaches. The study includes men newly diagnosed with low-risk prostate cancer. A 160 men will be recruited. Half of the men will receive a call from a health coach before their initial consultation visit with their urologist to review their treatment concerns and questions. The other half will receive usual care provided by the urologist, such as educational materials and services provided by the urologist.

NCT ID: NCT03396874 Not yet recruiting - Prostate Cancer Clinical Trials

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Start date: January 2018
Phase: Phase 2
Study type: Interventional

This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells. Together with a PET/CT scanner, the distribution of 68Ga-PSMA can be determined in the body. To test this new drug, participants will receive an intravenous injection of Ga-68-PSMA and then have a PET/CT scan. The scan results will be made available to study participants and treating physicians.

NCT ID: NCT03396848 Recruiting - Prostate Cancer Clinical Trials

Sexual Health and Rehabilitation eClinic (SHAReClinic)

Start date: August 23, 2017
Phase: N/A
Study type: Interventional

In addressing the need for effective post treatment support for men (and their partners) following treatment for prostate cancer, the investigators will employ an innovative SHAReClinic (Sexual health and Rehabilitation eClinic Program) that emphasizes: 1) a bio-medical component (erectile rehabilitation), focused on the long term return of erectile functioning firm enough for penetration with or without erectile agents/devices; and 2) a psychological component (intimacy maintenance), involving the maintenance or restoration of couples' intimacy. Through comparison research, the eClinic will be analyzed and made comparable in quality to the programs offered currently at leading institutions in major metropolitan areas, thus providing personalized, comprehensive cancer care to all Canadians.

NCT ID: NCT03392233 Recruiting - Breast Cancer Clinical Trials

Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors

Start date: August 18, 2017
Phase: Phase 2
Study type: Interventional

Stereotactic Body Radiation Therapy(SBRT) for spinal metastases has been proved a good results in pain relieve and local control, However,the longterm of efficacy and safety of this regimen is unclear.The purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be survival more than 2 years.

NCT ID: NCT03392181 Not yet recruiting - Prostate Cancer Clinical Trials

PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Start date: January 20, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to gain understanding of how PET-MR (positron emission tomography-magnetic resonance imaging) using the substance 18F-DCFPyL (PyL) may help in diagnosing prostate cancer and in determining the stage of prostate cancer before surgery.

NCT ID: NCT03389451 Not yet recruiting - Prostate Cancer Clinical Trials

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

Start date: January 31, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging. If this works, prostate cancer treatments can be prescribed that match the location of the disease. PSMA is radiolabeled with Gallium-68 (Ga-68). This means a participant receives a small dose of radiation from the drug - less than the annual radiation limit for a medical worker. To test this new drug, participants will receive an injection of Ga-68 PSMA and then have a PET scan. This PET scan, and the reported results, will be entered into the medical record and shared with the treating oncologists.

NCT ID: NCT03388619 Recruiting - Prostate Cancer Clinical Trials

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Start date: January 24, 2018
Phase: Phase 1
Study type: Interventional

Background: Sometimes prostate cancer comes back after a person s prostate is removed. In this case, radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective. It is usually given in short doses almost every day for 6 or 7 weeks. Researchers want to see if a shorter schedule can be as effective. They want to see if that causes the same or fewer side effects. Usually, radiation is used to treat the entire area where the prostate was before surgery. In some patients, an area of tumor can be seen on scans. Researchers are also trying to see if they can give less dose to the area usually treated with radiation if the full dose is given to the tumor seen on scans. Objective: To find the shortest radiation schedule that people can tolerate without strong side effects. Eligibility: People at least 18 years old who have had a prostatectomy and will get radiation Design: Participants will be screened with: - Medical history - Physical exam - Blood and urine tests - Scan that uses a small amount of radiation to make a picture of the body - Scan that uses a magnetic field to make an image of the body - Participants will provide documents that confirm their diagnosis. - Participants may have a scan of the abdomen and pelvis. Before they start treatment, participants will have another physical exam and blood tests. Participants will get radiation each day Monday through Friday. Treatment may last 2, 3, or 4 weeks. Participants may provide a tissue sample from a previous procedure for research. Participants will answer questions about their general well-being and function. About 4-5 weeks after they finish radiation treatment, participants will have a follow-up visit. They will be examined and give a blood sample. They will have 6 follow-up visits for the next 2 years.

NCT ID: NCT03388346 Not yet recruiting - Prostate Cancer Clinical Trials

68Ga PSMA in Preprostatectomy Patients

Start date: January 31, 2018
Phase: Phase 2
Study type: Interventional

This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging. If this works, prostate cancer treatments can be prescribed that match the location of the disease. PSMA is radiolabeled with Gallium-68 (Ga-68). This means a participant receives a small dose of radiation from the drug - less than the annual radiation limit for a medical worker. To test this new drug, participants will receive an injection of Ga-68 PSMA and then have a PET scan. This PET scan, and the reported results, will be entered into the medical record and shared with the treating oncologists.

NCT ID: NCT03387527 Not yet recruiting - Prostate Cancer Clinical Trials

Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening

Start date: January 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate a new counseling tool for patients deciding whether or not to undergo prostate cancer screening. This screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause. We are evaluating whether or not patients find this screening decision aid helpful. As part of this study, you will be asked for your response on questionnaires. Since we are interested in your opinion, there are no wrong answers. If patients find the screening decision aid helpful, we will make it available at other clinic locations.